Clinical Trials Logo

Recurrent Skin Carcinoma clinical trials

View clinical trials related to Recurrent Skin Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02964559 Active, not recruiting - Clinical trials for Skin Squamous Cell Carcinoma

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Start date: January 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02465060 Active, not recruiting - Multiple Myeloma Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Start date: August 17, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

NCT ID: NCT00954226 Active, not recruiting - Clinical trials for Recurrent Head and Neck Carcinoma

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Start date: August 5, 2009
Phase: Phase 1
Study type: Interventional

This randomized phase Ib trial studies standard-dose or high-dose erlotinib hydrochloride before surgery in treating patients with head and neck cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.